Seiger K, et al. – Although greater spending on oral anticancer agents should be spurred by increased access to care and broadening drug indications, prices have risen quicker than inflation and are not entirely reflective of innovation or effectiveness. Thus, researchers conducted a study to weight the proportional associations of increasing therapeutic expenses and use with increased Medicare Part D spending for a cohort of oral anticancer drugs used 2013-2017.